发现新型因达衍生物作为第二代TRK抑制剂
Qiaohua Qin1, Shuyu Lu1, Zhiqiang Guo1
1Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China.
新的英达TRK抑制剂通过准NTRK基因融合来对抗癌症. 化合物B31对抗耐药突变具有强大的活性,为NTRK融合阳性癌症提供了有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- NTRK基因融合是各种癌症的致癌驱动因素.
- 第一代TRK抑制剂 (拉罗特雷克提尼布,恩特雷克提尼布) 面临抗药性.
- 开发下一代TRK抑制剂至关重要.
研究的目的:
- 设计和合成新的英达TRK抑制剂.
- 对抗抗性细胞系的抗增殖活动进行评估.
- 评估化合物B31的疗效和药理动力学特性.
主要方法:
- 抑制剂设计的分子杂交策略.
- 新型英达TRK抑制剂的合成.
- 在体外抗增殖试验和体内药理动力学研究.
主要成果:
- 化合物B31对Km-12,Ba/F3-TRKAG595R,和Ba/F3-TRKAG667C细胞系表现出强烈的活性 (IC50:0.3,4.7,9.9nM).
- 与塞利特雷克提尼布相比,B31显示出对TRKAG667C的优异抑制.
- 化合物B31表现出中度的激酶选择性和出色的血稳定性 (t1/2>> 480分钟).
结论:
- 新型因达TRK抑制剂成功设计和合成.
- 化合物B31是治疗NTRK融合阳性癌症的有希望的候选者,包括具有抗性突变的癌症.
- B31在体外和体外表现出有利的药物动力学特征.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
相关概念视频
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
